FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200344305> ?p ?o ?g. }

• W4200344305 endingPage "279" @default.
• W4200344305 startingPage "271" @default.
• W4200344305 abstract "The last decade has seen an increase in the use of anti-seizure medications (ASMs); however, the burden of treating drug-resistant epilepsy has not fallen. We performed this meta-analysis to evaluate the optimal dose of Perampanel (PER) as a new adjunctive treatment for drug-resistant seizures.We searched for studies published from inception to February 1, 2021 from PubMed, Central Register of Controlled Trials (CENTRAL), and ScienceDirect. Research characteristics, patients' characteristics, and treatment regimen, concomitant ASMs, clinical outcomes were extracted. The practical outcome included a reduction in seizures frequency ≥50%, ≥75%, and ≥100% from baseline convulsive seizure frequency, and the safety outcome included the proportion of drug withdrawal and adverse reactions. Odds ratios (OR) for 95% confidence intervals (95% CI) were estimated by the inverse variance method.Four trials which enrolled 2187 participants (1569 in the PER group and 618 in the placebo group) were included. Results showed that 8 or 12 mg per day had the best effect on all three outcomes, with no significant difference between 8 and 12 mg per day (≥50% reduction, 35.5% vs 36.1%, P = .84; ≥75% reduction, 17.8% vs 19.1%, P = .64; seizure-free, 3.5% vs 3.7%, P = .85). In addition, 12-mg PER compared to 8 mg had a higher proportion of trial withdrawal (8.7% vs 17.0%; P < .00001) and treatment-emergent adverse event (TEAE) resulting in dose reduction/discontinuation (18.5% vs 32.0%; P < .00001). The adverse events (AEs) significantly associated with adjunctive PER were dizziness, somnolence, fatigue, and irritability.Adjunctive treatment of PER was associated with a more significant reduction in the frequency of seizures in patients with refractory epilepsy than placebo, but with a higher frequency of AEs. PER at a daily dose of 8 mg appears to have the best ratio between efficacy and tolerance in most study participants." @default.
• W4200344305 created "2021-12-31" @default.
• W4200344305 creator A5001647048 @default.
• W4200344305 creator A5051528018 @default.
• W4200344305 creator A5058217577 @default.
• W4200344305 creator A5067658278 @default.
• W4200344305 date "2022-02-02" @default.
• W4200344305 modified "2023-09-27" @default.
• W4200344305 title "The efficacy and safety of adjunctive perampanel for the treatment of refractory focal‐onset seizures in patients with epilepsy: A meta‐analysis" @default.
• W4200344305 cites W1498758291 @default.
• W4200344305 cites W1997135414 @default.
• W4200344305 cites W2003162600 @default.
• W4200344305 cites W2017422058 @default.
• W4200344305 cites W2043569242 @default.
• W4200344305 cites W2046259291 @default.
• W4200344305 cites W2116124097 @default.
• W4200344305 cites W2135808877 @default.
• W4200344305 cites W2145546535 @default.
• W4200344305 cites W2276241585 @default.
• W4200344305 cites W2332722423 @default.
• W4200344305 cites W2626721982 @default.
• W4200344305 cites W2772236704 @default.
• W4200344305 cites W2777270043 @default.
• W4200344305 cites W2808405323 @default.
• W4200344305 cites W2891964652 @default.
• W4200344305 cites W3094920716 @default.
• W4200344305 cites W4200344305 @default.
• W4200344305 cites W4230449467 @default.
• W4200344305 cites W4241136696 @default.
• W4200344305 doi "https://doi.org/10.1002/epi4.12574" @default.
• W4200344305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34951748" @default.
• W4200344305 hasPublicationYear "2022" @default.
• W4200344305 type Work @default.
• W4200344305 citedByCount "3" @default.
• W4200344305 countsByYear W42003443052022 @default.
• W4200344305 countsByYear W42003443052023 @default.
• W4200344305 crossrefType "journal-article" @default.
• W4200344305 hasAuthorship W4200344305A5001647048 @default.
• W4200344305 hasAuthorship W4200344305A5051528018 @default.
• W4200344305 hasAuthorship W4200344305A5058217577 @default.
• W4200344305 hasAuthorship W4200344305A5067658278 @default.
• W4200344305 hasBestOaLocation W42003443052 @default.
• W4200344305 hasConcept C118552586 @default.
• W4200344305 hasConcept C121332964 @default.
• W4200344305 hasConcept C126322002 @default.
• W4200344305 hasConcept C142424586 @default.
• W4200344305 hasConcept C142724271 @default.
• W4200344305 hasConcept C156957248 @default.
• W4200344305 hasConcept C168563851 @default.
• W4200344305 hasConcept C197934379 @default.
• W4200344305 hasConcept C204787440 @default.
• W4200344305 hasConcept C27081682 @default.
• W4200344305 hasConcept C2778186239 @default.
• W4200344305 hasConcept C2778715236 @default.
• W4200344305 hasConcept C2779034229 @default.
• W4200344305 hasConcept C2779384505 @default.
• W4200344305 hasConcept C2780836401 @default.
• W4200344305 hasConcept C2781413609 @default.
• W4200344305 hasConcept C3018162438 @default.
• W4200344305 hasConcept C42219234 @default.
• W4200344305 hasConcept C44249647 @default.
• W4200344305 hasConcept C71924100 @default.
• W4200344305 hasConcept C87355193 @default.
• W4200344305 hasConceptScore W4200344305C118552586 @default.
• W4200344305 hasConceptScore W4200344305C121332964 @default.
• W4200344305 hasConceptScore W4200344305C126322002 @default.
• W4200344305 hasConceptScore W4200344305C142424586 @default.
• W4200344305 hasConceptScore W4200344305C142724271 @default.
• W4200344305 hasConceptScore W4200344305C156957248 @default.
• W4200344305 hasConceptScore W4200344305C168563851 @default.
• W4200344305 hasConceptScore W4200344305C197934379 @default.
• W4200344305 hasConceptScore W4200344305C204787440 @default.
• W4200344305 hasConceptScore W4200344305C27081682 @default.
• W4200344305 hasConceptScore W4200344305C2778186239 @default.
• W4200344305 hasConceptScore W4200344305C2778715236 @default.
• W4200344305 hasConceptScore W4200344305C2779034229 @default.
• W4200344305 hasConceptScore W4200344305C2779384505 @default.
• W4200344305 hasConceptScore W4200344305C2780836401 @default.
• W4200344305 hasConceptScore W4200344305C2781413609 @default.
• W4200344305 hasConceptScore W4200344305C3018162438 @default.
• W4200344305 hasConceptScore W4200344305C42219234 @default.
• W4200344305 hasConceptScore W4200344305C44249647 @default.
• W4200344305 hasConceptScore W4200344305C71924100 @default.
• W4200344305 hasConceptScore W4200344305C87355193 @default.
• W4200344305 hasIssue "2" @default.
• W4200344305 hasLocation W42003443051 @default.
• W4200344305 hasLocation W42003443052 @default.
• W4200344305 hasLocation W42003443053 @default.
• W4200344305 hasOpenAccess W4200344305 @default.
• W4200344305 hasPrimaryLocation W42003443051 @default.
• W4200344305 hasRelatedWork W2015861704 @default.
• W4200344305 hasRelatedWork W2060121528 @default.
• W4200344305 hasRelatedWork W2985476322 @default.
• W4200344305 hasRelatedWork W3025569892 @default.
• W4200344305 hasRelatedWork W3211869309 @default.
• W4200344305 hasRelatedWork W4283817555 @default.
• W4200344305 hasRelatedWork W4288033808 @default.
• W4200344305 hasRelatedWork W4376618040 @default.

• next